Before admission to the trial, the abnormality is defined on the basis of at least three fasting plasma samples, using ultracentrifugation and heparin-manganese extraction procedures (Fredrickson et al. 1967) . Secondary hyperlipoproteinvmias (e.g. those due to thyroid, renal or hepatic disease) are excluded, as is concurrent serious disease and concomitant drug therapy, which may alter lipid levels (e.g. cestrogens) or which may interact with CI-719 (e.g. anticoagulants). Obesity and moderate alcohol intake are not exclusions, but women of child-bearing potential are excluded. Entrants must be on no other lipid lowering therapy (including diet) and have been off any previous lipid lowering therapy for at least six weeks.
The trial design involves preliminary classification of abnormality according to the Fredrickson criteria. The age-related limits of normality are those suggested by Fredrickson et al. (1967) . The first month is spent on placebo, which gives three further baseline assessments. During the next two months, patients take 800 mg of CI-719 daily, with monthly assessments. Subsequently, dosage varies from 400 mg to 1600 mg daily, with monthly assessment on fasting samples. The dosage is tailored to the minimum required to bring to and maintain lipid levels within the upper age-related limits of normality (Fredrickson et al. 1967) . The trial will run for six months of active therapy in the first instance.
This interim summary reports on 21 patients (19 male, 2 female, age-range 32-55, median 47 years). Three have a type Ilb, 15 a type IV and 3 a type V abnormality and have, with the exception of 1 type V patient, completed six months on the active drug.
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In the main, these patients constitute a 'high risk' group, where lipid lowering therapy would appear justified. Five had sustained a previous myocardial infarction (at least nine months before entry to the trial). Eight suffered from possible or probable angina pectoris, 4 had intermittent claudication, I had severe hypertension.
Results
Tables 1-3 give details of the relevant lipid   parameters. There was a significant fall for the whole group in total plasma triglycerides (P<0.001, paired t-test) on the active drug (800 mg/day), with a further fall as the dose is increased to 1600 mg/ day in resistant patients. Median triglyceride values are shown in Table 1 , as the true magnitude of the fall is obscured by very high triglyceride levels in a minority of patients.
There was a fall of some 10% in total plasma cholesterol, and analysis of lipoprotein cholesterol fractions showed this to be due almost entirely to a fall in VLDL cholesterol with insignificant falls in LDL cholesterol (2%), and no change in HDL cholesterol. Weight did not alter significantly during the period of study. Tables 2 and 3 give a more detailed analysis of particular patient groups. Table 2 shows the responses of 3 type V patients to the drug. Patient 1 demonstrated a constant triglyceride level before therapy. Introduction of CI-719 Cholesterol 6.9 5.9 9.7 6.6 5.6 6.2 6.0 6.6 5.8 8.0 5.9 6.3 Triglycerides 17.25 10.25 63.0 5.5 3.3 10.5 15.5 6.9 9.8 9.0 21.0 13.25 LDL cholesterol biochemical screening, which included full blood count, differential white count, platelet count, bilirubin, transaminases, alkaline phosphatase and urea estimation at each assessment. Random abnormalities only were found. There was no evidence of an abnormality developing and persisting on the active drug. There was no clinical evidence of hepatomegaly.
Two patients were withdrawn from the trial. One defaulted after 17 weeks of active therapy. One with a type V abnormality (Patient 3, Table  2 ) developed an exacerbation of pre-existing eruptive xanthomata of the buttocks, and he was withdrawn after 16 weeks of active therapy.
It should be noted that all patients maintained the same lipoprotein abnormality in at least five of their six pre-therapy analyses.
Conclusion
In summary, CI-719 is an effective and safe plasma triglyceride lowering agent. Its effect is still significant although lessened in the presence of moderate to heavy alcohol ingestion, and therapy failure appears, probably owing to high alcohol intake or bout drinking. LDL cholesterol is little altered and the 10% fall in plasma cholesterol is due to a fall in plasma VLDL cholesterol.
Significant triglyceride falls occur in types IV, lIb and V patients. The rise in HDL cholesterol noted in 2 patients might have potential therapeutic value, as high HDL levels appear to protect against atheroma (Carew et al. 1976 ), but chi-squared statistical analysis showed that this finding was not significantly different from chance at the 5 % probability level.
The response of the type V patients is important as it appears that this lipoprotein abnormality carries a high risk of coronary artery disease (Fallat & Glueck 1976 ).
II. STUDIES ON MECHANISM OF ACTION OF CI-719
In an attempt to elucidate the possible mechanism of action of CI-719 on triglyceride metabolism, turnover studies and estimations of lipolytic activity were performed on 11 patients before and during therapy, utilizing an infusion of labelled palmitic acid.
Patients and Methods
Eleven patients were studied; 2 had a type lIb, 2 a type V and 7 a type IV abnormality. Of the type IV patients, 4 belonged to subgroup 2 (Patients 1, 4, 6, 7) and 3 to subgroup 1. effected a dramatic drop in total triglyceride and VLDL cholesterol levels with a further significant, maintained reduction as the dose was raised to 1600 mg/day. LDL and HDL cholesterol levels rose, but remained within the normal range. This suggests that CI-719 may be effective in treating some type V patients. Significantly, this patient is teetotal.
Patient 3 showed wide fluctuations in pretherapy triglyceride levels (owing probably to varying alcohol intake). After 16 weeks, triglyceride levels had reached their lowest recorded level owing, presumably, to a period of relative abstinence from alcohol and to drug therapy. This patient was then withdrawn from the trial (see later). Patient 2 showed no obvious response to therapy (up to 1600 mg/day). This patient works as a barman, and probably has a steady high alcohol intake.
This analysis suggests that CI-719 is effective in type V patients, but its efficacy may be offset (Patient 2) or even annulled (Patient 3) by alcohol ingestion.
Type IV patients were subdivided in the light of the foregoing into subgroups (Table 3) , once alcohol intake was revealed as patients became better known to us. In group 1 (n=8) alcohol intake was very low and in group 2 (n=7) intake was considered moderate to heavy. Members of this latter group were drinking most nights or heavily at the weekends, or went on intermittent bouts.
Group 1 demonstrated a smaller variation in pre-therapy triglyceride levels, with an excellent response to CI-719. Only 1 patient has not reached a 'normal' triglyceride level (on 1600 mg/ day) and 3 patients are controlled on 400 mg of CI-719 daily. The 2 women patients fall into this group. There was no significant change in LDL cholesterol before and during therapy, but 2 patients developed a significant rise in HDL cholesterol levels during therapy (P<0.01, paired t-testing of pre-therapy and therapy values for each patient). Total cholesterol fell by 10% owing to a fall in VLDL cholesterol.
Group 2 had wide variations in pre-therapy triglyceride levels and were more resistant to therapy. Two patients remained uncontrolled with rises in plasma triglycerides probably caused by alcohol ingestion. No significant changes in the LDL and HDL cholesterol were noted. Adverse effects were sought by interrogation, clinical examination and hmmatological and Subjects were admitted to hospital for 24 h after an overnight fast of 13 h. Then 20-25,uCi of [1-14C] potassium palmitate, complexed to human serum albumin (as a 20% solution) was infused into an antecubital fossa vein as a 2 ml volume over a 2 h period, using a Sage pump.
An intravenous cannula was inserted for venesampling into the contralateral arm and kept patent by a slow, non-heparinized saline flush. Before sampling, the first 2 ml of blood was discarded to allow for himodilution.
During the second hour of infusion, six samples were withdrawn and centrifuged, and EDTAanticoagulated plasma was frozen and transported to the laboratory for extraction of free Results Table 4 lists the relevant kinetic data. Free fatty acid flux in umol/min at equilibrium is calculated as the rate of infusion of label (DPM/min) divided by the specific activity at equilibrium (DPM/,mol). The tabulated values are the means of six samples.
A plot of triglyceride specific activity against time was exponential for at least 10 hours after the infusion, and this part of the curve was set out in a semi-logarithmic graph to give a value for K, the fractional turnover rate, calculated as 0.693/ti, where ti is the half-life of the labelled triglyceride. The plasma VLDL triglyceride turnover rate in ,umol/h per kg is then given by the product of K x plasma VLDL concentration the Dole method (1956) , with subsequent separation by silica gel, thin layer chromatography and assay by gas-liquid chromatography, using heptadecanoic acid as internal standard.
After terminating the infusion, samples were obtained at intervals over the next 20 h and triglycerides and fatty acids were obtained by Dole extraction and heptane-ethanediol separation. Triglycerides were assayed by the method of Kessler & Lederer (1966) . Counting was performed in non-aqueous PPO/POPOP scintillant.
Patients were given fat-free meals at 3 and 7 p.m. Lipase activity was assayed in pre-and post-heparin plasma (5000 u i.v.) in the fasting state, the following morning, by the method of Weir et al. (1972). (,mol/ml) x 50, where the VLDL distribution space is taken as the plasma volume (50 ml/kg body weight).
Eight of the 11 patients showed an increase in lipase activity on therapy. There was a marked decrease in free fatty acid turnover in all patients except 1 type V (Patient 11, Table 4 , also referred to as Patient 2 in Table 2) , who showed no response to therapy. This patient, however, did show an increase in lipolytic activity.
Changes in free fatty acid flux correlated with changes in serum triglyceride concentrations (r=0.845, P<0.01). Turnover rates of triglyceride were similarly reduced with therapy, and the change in triglyceride turnover rate correlated with the change in triglyceride concentration (r=0.514) and with pre-therapy turnover rate (r=0.893). The change in plasma triglyceride Patient I (IV) 2 (IV) 3 (IV) 4 (IV) 5 (IV) 6 (IV) 7 (IV) 8 (Ilb) 9 (IIb) 10(V) 11 (V) 0.6 -±1.1 concentration correlated with pre-therapy plasma triglyceride concentration (r =0.866).
The analysis in the last paragraph relates to the type IV and type Ilb patients considered together. Type V data have not been included in this analysis.
It should also be noted that the lipase assay used here measures non-specific plasma lipolytic activity.
Discussion
The use of this method makes several major assumptions. Firstly, the technique implies that free fatty acid specific activity is constant during the second hour, and indeed this was found to be so. It has been demonstrated using this infusion technique that the plasma-specific activity of the free fatty acids is equal to the specific activity in lymph, and therefore the plasma component is in equilibrium with the lymph compartment (Kissebah et al. 1974), i.e. steady state conditions obtain.
Secondly, the VLDL distribution space is considered to be the plasma space and this has also been validated .
Similarly, Kissebah, et al. have shown that the error involved in using total plasma triglycerides instead of VLDL triglyceride is less than 5%. Finally, the back reaction of plasma VLDL tri-glyceride to plasma free fatty acid has been shown to contribute less than 5% of plasma free fatty acid turnover rate .
The data presented here suggest that CI-719 acts by reducing free fatty acid flux and triglyceride turnover rate.
There is an augmentation of lipase activity in the majority of patients, but this may be due to a lowering of plasma triglyceride levels. This is supported by the lack of correlation of lipase activity with changes in fatty acid flux or triglyceride turnover rate. Also, 2 individuals (Patients 7 and 8, Table 4 ) showed marked alterations in turnover rate of triglycerides with therapy, but no significant change in lipase activity, suggesting that the activity of this drug is directed primarily to a site other than lipase.
